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Abstract
Current prophylactic vaccines work via the induction of B and T cell mediated memory that effectively control further
replication of the pathogen after entry. In the case of therapeutic or post-exposure vaccinations the situation is far more
complex, because the pathogen has time to establish itself in the host, start producing immune-inhibitory molecules and
spread into distant organs. So far it is unclear which immune parameters have to be activated in order to thwart an existing
lethal infection. Using the mousepox model, we investigated the immunological mechanisms responsible for a successful
post-exposure immunization with modified vaccinia Ankara (MVA). In contrast to intranasal application of MVA, we found
that intravenous immunization fully protected mice infected with ectromelia virus (ECTV) when applied three days after
infection. Intravenous MVA immunization induced strong innate and adaptive immune responses in lethally infected mice.
By using various gene-targeted and transgenic mouse strains we show that NK cells, CD4 T cells, CD8 T cells and antibodies
are essential for the clearance of ECTV after post-exposure immunization. Post-exposure immunization with MVA is an
effective measure in a murine model of human smallpox. MVA activates innate and adaptive immune parameters and only a
combination thereof is able to purge ECTV from its host. These data not only provide a basis for therapeutic vaccinations in
the case of the deliberate release of pathogenic poxviruses but possibly also for the treatment of chronic infections and
cancer.
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Introduction
Prophylactic vaccination, meaning the prevention of an
infectious disease by administration of attenuated or killed
pathogens or subunits thereof, remains one of the most important
measures to maintain public health. The list of vaccine-
preventable diseases currently includes 27 diseases, ranging from
Anthrax to Yellow Fever (http://www.cdc.gov/vaccines/vpd-vac/
default.htm). The large-scale vaccination with live vaccinia virus
(VACV) that led to the worldwide eradication of variola virus
(VARV), the causative agent of smallpox, is often cited as the most
successful vaccination program [1]. However, people born after
the cessation of the general smallpox vaccination in the late 1970’s
are at risk of poxvirus infections. Besides accidental or intentional
(bioterrorism) release of VARV, zoonotic poxvirus infections (e.g.,
monkeypox) also have to be envisaged as potential threats [2]. This
has lead to several governments stockpiling traditional smallpox
vaccines based on VACV, although the associated side effects of
the wide spread use of smallpox vaccines based on replicating
VACV [3,4] probably restrict their use to an emergency or post-
exposure situation. Thus, in cases of sudden outbreaks, caused
either naturally or through bioterrorism, efficient and fast acting
treatments have to become available.
As an alternative to the usage of antibiotics and antivirals to
combat existing infections the idea of therapeutic vaccination is
becoming increasingly attractive. This approach is currently
investigated mainly for the treatment of chronic infections and
cancer. The restricted use of traditional VACV smallpox vaccines
due to safety concerns, particularly for people with impaired
immune systems [5] has led to the development of potentially safer
alternative vaccines based on a highly attenuated, non-replicating
poxvirus, Modified Vaccinia Ankara (MVA; reviewed in [6,7].
Recent studies of our group [8] and others [9,10], have
demonstrated the efficacy of post-exposure vaccination in an
acute and lethal virus infection model using MVA or ECTV. In
this model mice were intranasally infected with ectromelia virus
(ECTV), the causative agent of mousepox. The course of disease is
very similar for mousepox and smallpox, including the entry route,
the high infectivity at low doses, the development of viremia, the
restricted host range and the delayed but fatal outcome (reviewed
in [11]). Therefore, mousepox can be regarded a valuable small
animal model for human smallpox and, in general, as a model for
acute, fatal viral diseases.
While many associate the efficacy of prophylactic VACV
immunization to be reliant on the induction of antibody responses
(for review see [12]), the requirements for a successful therapeutic
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ECTV infected C57BL/6, Toll Like Receptor (TLR) 9 deficient
and interferon a receptor (IFNAR) deficient, but not recombina-
tion-activating gene (Rag) 1 deficient mice could be protected by
simultaneous or post-exposure (only TLR9
2/2) immunization
with MVA [8]. These and other data [9] demonstrate that the
induction of adaptive immune responses is critical for a successful
therapeutic immunization in the mousepox model. Since the
essential roles of both innate and adaptive immune responses in
the survival of a primary ECTV infection have been well
established [13–20], we sought to define their respective roles in
a therapeutic vaccination protocol.
The highly attenuated MVA has a better safety profile and
fewer immunomodulatory molecules than live VACV and is
known to induce antibody and T cell responses in mice and
humans [6,7,21]. Furthermore, it was superior in postexposure
immunizations [9]. We therefore used MVA in order to define the
immunological requirements for the therapeutic protection of mice
from a lethal ECTV infection. Through the use of various
transgenic and knock-out mice we clearly demonstrated that only
a combination of NK cells, neutralizing antibodies, CD4 and CD8
T cells is able to thwart a lethal ECTV infection after therapeutic
MVA vaccination. Crucially, in this model we show that the
efficacy of this therapeutic vaccination strongly depends on the
immunization route.
Results
ECTV infected C57BL/6 mice can be rescued by
intravenous post-exposure MVA immunization.
Previously we were the first to demonstrate the feasibility of a
therapeutic vaccination regimen in an otherwise lethal orthopox-
virus infection [8]. In this case we rescued C57BL/6 mice from a
lethal mousepox infection by immediate vaccination with MVA.
In addition, we protected highly susceptible TLR9-deficient mice
with intranasal MVA immunization even two days after ECTV
infection. In this setting all mice survived without any obvious
signs of illness. A period of three days between infection and
immunization still conferred partial protection. In the light of these
promising results we sought to further investigate the potential and
the immunological mechanisms of therapeutic vaccination with
MVA.
First, we wanted to know whether our findings in TLR9-
deficient mice, which are 100-fold more susceptible to ECTV
infection [8], are transferrable to C57BL/6 wild type mice.
C57BL/6 mice were infected with a lethal dose of 30000
TCID50 of ECTV (of note, this dose is about 300 times higher
than the one used for TLR9
2/2 mice [8] and corresponds to
,14 LD50) and immunized two days later with MVA. Because
ECTV is able to spread from a local infection site to peripheral
organs, such as spleen, liver and ovaries, we included a systemic
immunization route. Only the systemic intravenous immuniza-
tion protected all mice from death, whereas only one out of three
intranasally vaccinated mice survived (Fig. 1A). If MVA
immunization was performed three days after infection, all
intranasally immunized mice died with the same kinetics as
unvaccinated control mice, but still none of the intravenously
vaccinated mice succumbed (Fig. 1B). The intravenous applica-
t i o no n l yw a sl e s sp r o t e c t i v ei fw ew a i t e df i v ed a y sb e f o r eM V A
vaccination and in this case only one out of five animals survived
(Fig. 1C). However, mice immunized 5 days after ECTV
infection died with delayed kinetics compared to the control
group.
Early activation of innate and adaptive immune
responses after intravenous post-exposure MVA
immunization.
Previous experiments of our group and others demonstrated a
partial role of innate and a crucial role of adaptive immunity for
the survival of ECTV infected mice even after immediate
application of MVA [8,9]. This and the fact that intravenous
post-exposure MVA immunization was far more potent than
intranasal immunization, prompted us to further investigate the
immunological differences between both application routes. All
further experiments were performed with a period of three days
between ECTV infection and MVA immunization. First, we
evaluated the innate immune response by measuring the levels of
19 cytokines immediately after MVA immunization. Six hours
after intravenous immunization, high serum levels of MCP-1,
MCP-3, Rantes, IL-6, IL-18 and IFN-c could be detected (Fig. 2).
Cytokine levels after intranasal MVA application were either
below the detection limit or indistinguishable from the levels in the
control group.
Next, we assessed the activation of NK and T cells in the spleen
one day after MVA application. In order to directly identify cells
that are actively synthesizing granzyme B in vivo, we adapted the
method developed by Liu et al. [22] and injected 250 mg brefeldin
A into all mice six hours prior to intracellular cytokine staining.
The activation status was further evaluated by the expression of
CD69. In control mice and mice intranasally immunized with
MVA about one third of all splenic NK cells expressed high levels
of granzyme B and CD69 (Fig. 3A and B). In intravenously
immunized mice the frequency went up to 87% (63.6%). A
similar pattern became apparent when monitoring T cell
activation: CD69 upregulation (CD4 and CD8 T cells) and
granzyme B expression (only CD8 T cells) was only detectable
after intravenous, but not intranasal MVA immunization. Thus,
intravenous post-exposure MVA immunization induced a rapid
strong innate and adaptive immune response as shown by the
systemic production of cytokines and the activation of NK and T
cells.
Intravenous post-exposure MVA immunization induces
stronger adaptive immune responses than intranasal
immunization.
Previous experiments have shown that Rag1-deficient mice,
lacking mature B and T cells, could not be rescued from lethal
ECTV infection by cotreatment with MVA [8,9]. These findings
argued for a crucial role of adaptive immune responses in the post-
exposure MVA vaccination model and thus we monitored
antibody and CD8 T cell responses in our setting.
In the serum of control mice and intranasally immunized mice,
vaccinia-specific IgG levels could first be detected at day 9 post
infection (Table 1). At this time point, a neutralizing capacity as
measured by a plaque reduction neutralization (PRNT) assay
could be detected in both groups. Interestingly, the mouse with the
highest IgG and PRNT titer on day 12 in the control group
survived, whereas all other mice from those two groups died. In
stark contrast, intravenous MVA immunization induced earlier
and more vaccinia-specific IgG with higher PRNT titers. Again,
all mice from this group survived without any symptoms. Of note,
there was a high degree of linear correlation between ELISA and
PRNT data (r=0.93 for day 9 and r=0.97 for day 12),
demonstrating a direct link between antigen-specific IgG titers
and the capacity to neutralize live vaccinia virus.
The B820–27 fragment of the soluble IFN-c receptor B8 of
vaccinia virus was identified as the immunodominant CD8 T cell
Therapeutic Pox Vaccination
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B820–27 has been shown to be conserved amongst different
poxvirus species [23]. In addition, peptide immunization with this
epitope confers protection against ECTV challenge [23]. In order
to evaluate vaccinia-specific CD8 T cell responses, we thus stained
spleen cells eight days after ECTV infection with MHC class I
multimers loaded with the B820–27 peptide. Again, only intrave-
nous MVA application induced significantly more B8-specific
CD8 T cells compared to non-immunized control mice (P#0.005)
(Fig. 4 and B). Intranasally immunized and control mice had the
same frequency of splenic B8-specific CTL.
Taken together, these experiments show clearly that after
intranasal post-exposure MVA immunization both innate and
adaptive immune responses were not enhanced above the
threshold already reached with ECTV infection. In stark
contrast, intravenous application of MVA three days after
ECTV infection efficiently activated and enhanced both arms of
the immune system over and above the threshold already
reached by the ECTV response. Because we only measured
systemic immune responses, we cannot exclude local immune
stimulation by intranasal immunization, which, however, would
have been insufficient to protect ECTV infected animals in our
model.
Innate and adaptive immune mechanisms are crucial for
a successful post-exposure MVA immunization
The above experiments showed that innate and adaptive
immune responses already induced by ECTV could be further
enhanced by intravenous immunization even when MVA was
applied three days after ECTV. Apparently the time window for a
successful post-exposure immunization is rather narrow (Fig. 1C),
making it likely that the time between immunization and a
putative death must be long enough to develop or to enhance
adaptive immunity. Previous results in Rag1-deficient and
IFNAR-deficient mice [8,9] suggest that both innate and adaptive
immune mechanisms are necessary for the survival of ECTV
infected mice. However, it remains unclear which part or parts of
the immune system are responsible for a successful post-exposure
MVA immunization. In order to further define the individual
immune mechanisms we took advantage of several transgenic and
knock-out mouse strains.
As intravenous post-exposure MVA immunization was the most
effective route in our model, we focused on this route for further
studies. In all experiments non-immunized and 3 day post-
exposure MVA immunized wild-type mice served as negative and
positive controls, respectively. For clearer presentation of the
results, groups are ordered according to mouse strains and
cumulative results from several experiments are shown for
individual mouse strains.
From a total of 44 ECTV infected C57BL/6 mice, 6 animals
survived (survival=13.63%) (Fig. 5A). These animals showed
clear symptoms of infection (conjunctivitis, hunched back, ruffled
fur, lethargy) between day 8 and 20 post infection and later
d e v e l o p e dt a i ll e s i o n sa n di ns o m e cases swollen limbs (data not
Figure 1. Intravenous post-exposure MVA immunization
provides better protection than intranasal immunization.
C57BL/6 mice were infected intranasally with 3610
4 TCID50 of ECTV.
Mice were left untreated or immunized after 2 (A), 3 (B) or 5 (C) days
with 5610
7 TCID50 of MVA either intravenously or intranasally. Note, in
C no i.n. group was included. Survival was monitored for 32 days. The
experiments were performed with 3–5 mice/group. Experiments for A
were performed twice, for C once and B shows one exemplary
experiment out of three.
doi:10.1371/journal.pone.0009659.g001
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positive control group died (survival=95.12%). Importantly,
none of the surviving animals in this group showed signs of
infection at any time point.
NK cells
NK cells were previously found to be crucial for the early
control of ECTV in C57BL/6 mice [20] and were highly activated
after intravenous MVA immunization (Fig. 3). Therefore, we
wanted to assess the role of NK cells in our model. For this
purpose, we took IL-15Ra deficient mice and their corresponding
control strain B6129SF2/J. IL-15Ra
2/2 mice lack NK and NKT
cells, but also have reduced numbers of CD8 T cells and cd
intraepithelial lymphocytes [24]. NKT cells, ab T cells and cd T
cells, however, do not exhibit antiviral function early after ECTV
infection [20]. Similar to C57BL/6 mice all MVA treated control
mice were fully protected (Fig. 5B). In contrast, 9 out of 11 IL-
15Ra
2/2 mice died within 18 days after infection. Most mice
(89%) died between day 9 and 11, suggesting an early role of NK
cells for the control of ECTV infection.
Figure 2. Intravenous but not intranasal post-exposure MVA immunization induces strong systemic cytokine production. C57BL/6
mice were infected intranasally with 3610
4 TCID50 of ECTV. Mice were left untreated or immunized after 3 days with 5610
7 TCID50 of MVA either
intravenously or intranasally. 6 hours after MVA immunization mice were bled and serum cytokine levels were determined using a bead-based
detection assay. Data are means 6 SD of 5 mice per group and are representative of three similar experiments. (n.d. = not detectable)
doi:10.1371/journal.pone.0009659.g002
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Antibodies seem to be critical for recovery from primary and
secondary ECTV infection [13,25]. In order to define the role of
antibodies, we used several mouse strains with individual defects in
the generation or functioning of antibodies. First, we used a B-cell
receptor transgenic mouse (T11mMT), which can only produce
antibodies of the IgM subclass specific to vesicular stomatitis virus
(VSV) that is antigenetically unrelated to ECTV [26–28]. These
mice were used instead of B cell deficient (mMT) mice, because
mMT mice show a distorted splenic microarchitecture resulting in
a defective T cell response [29,30]. All but one ECTV infected and
MVA immunized T11mMT mice died rapidly between day 10 and
11 after infection (Fig. 5C). These data imply that vaccinia-specific
antibodies are needed early during the infection.
In order to further define the required isotypes, we infected AID
deficient mice with ECTV and immunized them three days later
with MVA. AID deficiency causes a complete defect in class
switching, but also leads to a hyper IgM syndrome [31]. We
observed a survival of ,52% with staggered death kinetics
(Fig. 5C). In line with previous reports [31] surviving AID
2/2
mice had no detectable vaccinia-specific IgG1 or IgG2c titers, but
showed high IgM titers (data not shown). In order to test whether
the IgM containing sera have neutralizing capacity we performed
a PRNT assay with pooled sera from four surviving mice.
Interestingly, we found a neutralization titer in the range of wild
type mice (data not shown). These results imply that the
generation of IgG is important, but not essential for a successful
post-exposure immunization. High neutralizing IgM titers seem to
be at least partly protective in the case where no virus-specific IgG
can be generated.
Apart from the direct neutralization of a pathogen, antibodies
can activate NK cells and macrophages via Fc-receptors (FcR), a
process referred to as antibody dependent cellular cytotoxicity
(ADCC). NK cells exclusively express FccIIIR and in the absence
of this receptor NK cells lose their ADCC capacity but still can
lyse YAC-1 target cells. Mice deficient in FccIIIR, were partially
Figure 3. Intravenous but not intranasal post-exposure MVA immunization activates NK and T cells. C57BL/6 mice were infected
intranasally with 3610
4 TCID50 of ECTV. Mice were left untreated or immunized after 3 days with 5610
7 TCID50 of MVA either intravenously or
intranasally. 1 day after MVA immunization mice received an injection of 250 mg BFA and 6 hours later spleens were removed, stained and analyzed
by FACS. (A) Representative contour plots are shown for NK cells (NK1.1
+ CD3
2) and CD8 T cells (NK1.1
2 CD3
+ CD8
+). The frequency of
GranzymeB
+CD69
+ NK cells (upper panel) and CD8 T cells (lower panel) is shown in (B). (C) Representative histograms are shown for CD4 T cells
(NK1.1
2 CD3
+ CD4
+). The frequency of CD69
high CD4 T cells is shown in (D). Data are means 6 SD of 4–5 mice per group. The experiment was
repeated once with a similar outcome.
doi:10.1371/journal.pone.0009659.g003
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(Fig. 5C), indicating that ADCC can be compensated by other,
potentially overlapping, protective mechanisms of antibodies.
Mice lacking the FcRc chain have defects in expression or
signaling of FceR I and FccR I, II, III, IV [32]. Despite the
pleiotrophic immune defects seen in those mice, they were fully
protected with MVA post exposure vaccination (Fig. 5C). These
data imply that FcR mediated effects of antibodies are not
important in this setting.
Another possibility of antibody mediated virus clearance is the
activation of the complement cascade. In order to define the role
of the complement cascade for post-exposure MVA immunization
we took advantage of C3 deficient mice. C3 is an essential
component of the classical, alternative and lectin pathway. Thus,
C3
2/2 mice are unable to activate the cell-killing membrane
attack complex and lack the opsonizing function of C3 itself [33].
In our post-exposure setting, however, the complement system
seems to play no role because only 1 out of 8 mice died (Fig. 5C).
Taken together, the experiments above demonstrated an
essential role for antibodies in post- exposure MVA mediated
protection. Antibodies of different isotypes may neutralize virus,
activate complement and may interact with Fc receptors. As
complement and Fc receptors analyzed singly had no profound
effect, these systems may function cooperatively or compensate
each other.
T cells
In a last set of experiments we wanted to define the role of T
cells in the survival of ECTV infected and MVA immunized mice.
We thus infected MHC class I (b2M
2/2) and II (H2-Ab1
2/2)
knock out mice and monitored the survival after MVA
immunization. MHC class I knock out mice remained healthy
for about three weeks and then started to die with a survival rate of
25% (Fig. 5D). In contrast to MHC Class I deficient mice, MHC
class II deficient mice already started to die at day 8 post infection
and only ,5% survived (Fig. 5D).
Thus, both T cell subsets participate in the clearance of ECTV
after post-exposure MVA immunization, but each subset is
required at a different time point after infection.
Discussion
Due to the successful eradication of VARV and the severe
adverse effects associated with VACV vaccination, prophylactic
mass vaccination was halted in the 1980s. The current threat of
bioterrorism and the possible emergence of human monkeypox
have sparked interest in alternative anti-poxvirus therapies. In
addition to antiviral pharmaceuticals, vaccination shortly after
infection would be such an alternative.
We and others have recently employed the mousepox model in
order to investigate the potential of post-exposure immunizations
[8–10]. ECTV, the causative agent of mousepox, can be naturally
found in wild mice. Several isolates have been described since its
first discovery in 1929 [34] and ECTV strain Moscow is the most
virulent [35,36]. The pathogenesis of smallpox in humans caused
by VARV infection is closely mirrored by mousepox, especially in
C57BL/6 mice [10]. Both viruses infect their respective hosts at
low doses and cause severe systemic diseases (reviewed in [11]).
Comprehensive studieshavefocused ontherevelationofimmune
parameters necessary for the survival of primary and secondary
ECTV infection. For primary infections, these studies have
demonstrated an essential role of innate and adaptive immunity,
including TLR9 mediated recognition by DC [8], the complement
system [18], NK cells [15,20], type I and II IFNs [16,19], B cells
[13,14], CD4 T cells and CD8 T cells [14,17]. In the case of
secondary infections, i.e., after prophylactic vaccination or non-
lethal ECTV infections, virus-specific antibodies and B cell memory
Table 1. Geometric mean titers of antibodies.
Group Mouse IgG titer (ELISA) PRNT titer Day of death
day 6 day 9 day 12 day 6 day 9 day 12
control 1 1 247 2560 1 6 1289
2 1 200 n.a. 1 125 n.a. 14
3 1 224 1453 1 207 274 13
4 1 246 n.a. 1 73 n.a. 11
5 1 100 1495 1 91 221 15
MVA i.v. 1 50 1694 7125 1 1875 3774
2 50 704 3282 1 485 1493
3 50 1640 5538 6 1056 3112
4 50 1288 6885 1 963 3508
5 50 2863 8524 6 1662 3403
MVA i.n. 1 1 239 1642 1 161 462 17
2 1 241 n.a. 1 106 n.a. 9
3 1 n.a. 1015 1 n.a. 535 16
4 1 100 644 1 91 236 23
5 1 268 n.a. 1 307 n.a. 11
C57BL/6 mice were infected with 3610
4 TCID50 of ECTV intranasally. Mice were left untreated or immunized three days later with 5610
7 TCID50 of MVA either
intravenously or intranasally. Anti-MVA IgG titers were calculated by linear regression and defined as the serum dilution that resulted in an optical density of 0.30. Sera
with OD value below 0.3 set to titer of 1 (negative). Geometric mean of neutralizing antibody titers by PRNT were determined as serum dilution able to neutralize 50%
of the virus. Similar results were obtained in a separate experiment.
n.a. not applicable (mouse was dead or bleeding was not possible).
doi:10.1371/journal.pone.0009659.t001
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challenge [19,25,37]. However, in a therapeutic setting, where
ECTV has a timely advantage, the requirements might be different.
Therefore, we sought to define the immunological mechanisms of
post-exposure immunization in the mousepox model. So far, MVA
[8,9], VACV-Lister [9] and ECTV [10] have been used for post-
exposure immunizations. Due to its superior safety-profile, the
advanced stage in clinical trials and better protective capacity in a
post-exposure setting [9] we chose MVA as vaccine.
In our previous study we applied MVA either subcutaneously or
intranasally [8]. Paran et al. found different survival rates after
intradermal, intramuscular and intranasal immunization [9]. In
order to find the vaccination route with the highest protective
capacity we compared subcutaneous, intranasal and intravenous
MVA application. As subcutaneous vaccination was not protective
in our setting when given two days after infection with a lethal
dose of ECTV (data not shown) we omitted this route from further
experiments. Intranasal immunization was only partially protec-
tive when given after two days, but not at all when given three days
after ECTV. This contrasts with our findings in TLR9 deficient
mice and lower doses of ECTV, where intranasal immunization
was completely protective when applied after two days [8].
In the present study, wild-type C57BL/6 mice were infected
with 30000 TCID50 of ECTV. This infection dose was 300-fold
higher than that previously used with TLR9 deficient mice that
are at least 100-fold more susceptible to ECTV infection. We
hypothesized that this higher dose might have led to earlier virus
dissemination and the production of more immune-inhibitory
molecules, rendering a local immunization strategy less effective.
We envisaged that the superior efficacy of the intravenous
application route might be due to the induction of stronger
immune responses. Indeed, intranasal MVA immunization did not
further enhance the immune response already induced by ECTV
(Figs. 1, 2, 3, 4). In stark contrast, intravenous immunization
induced strong innate (cytokines, NK cells) and adaptive (CD4 and
CD8 T cells, B cells) immune responses.
Among the detected cytokines, IFN-c has been shown to be
crucial for recovery of C57BL/6 mice from mousepox [16]. IL-18
was initially identified as an IFN-c inducing factor and activates
NK cells, which also play a critical role in the control of an ECTV
infection [20,38]. A recent study by Wang et al. found that IL-18
together with IL-12p40 is necessary for ECTV control and
recovery from infection [39]. Interestingly, Rantes, IL-18 and
IFN-c promote Th1 responses, the type of immune response that
has been implicated in the recovery from orthopoxvirus infections
in mice and humans [10,40,41]. The chemokine MCP-1 was
recently found in the lungs of C57BL/6 mice intranasally
immunized with MVA [42]. Lehmann et al. detected this cytokine
two days after immunization in bronchoalveolar lavage fluid. We
did not detect any MCP-1 in serum of mice six hours after
intranasal MVA immunization and this was independent of
whether the mouse was ECTV infected or not (Fig. 2 and data not
shown). It thus could be that after intranasal application of MVA
MCP-1 is produced later and only locally. In a therapeutic setting,
where ECTV has three days to replicate, a local production of
cytokines would be antagonized by the production of immune
evasion molecules. Importantly, five of the six detected cytokines
after intravenous immunization can be directly neutralized by the
ECTV proteins: viral chemokine binding protein (Rantes, MCP-1
and MCP-3) [43], B8 (IFN-c) [44] and the viral IL-18 binding
protein (IL-18) [45]. Since intranasal MVA immunization is only
fully protective in C57BL/6 mice when given within one day of
infection [8,9], we hypothesize that one reason for the lower
protective capacity of this immunization route is the neutralization
of locally produced cytokines and chemokines by viral binding
proteins. Because variola virus encodes a related set of immune
evasion molecules, similar neutralization mechanisms are likely to
occur in humans after infection with this virus.
In line with the strong systemic cytokine production, we also
observed a strong activation of NK and T cells after intravenous
MVA immunization (Fig. 3). NK cells and CD4 and CD8 T cells
play important roles in the recovery from a primary ECTV
infection [14,15,17,20]. In these previous studies mice were
infected with a virus dose that is not lethal to wild-type C57BL/
6 mice. After infection with a lethal dose, however, these cells are
apparently not activated appropriately to eliminate ECTV (Fig. 3).
This deficit can be overcome by intravenous but not intranasal
post-exposure MVA immunization. Our studies with gene
targeted mice proved that all three cell types are important for
the recovery from a lethal mousepox infection after post-exposure
immunization (Fig. 5). We found an unexpected chronological
order in which these cells are required. NK cells and CD4 T cells
are essential within the first two weeks of infection. Surprisingly,
CD8 T cells become essential only after three weeks. Because
MHC class II deficient mice die earlier than MHC class I deficient
mice the essential function of CD4 T cells seems not to be the help
Figure 4. Intravenous post-exposure MVA immunization
induces stronger antigen-specific CD8 T cell response than
intranasal immunization. C57BL/6 mice were infected intranasally
with 3610
4 TCID50 of ECTV. Mice were left untreated or immunized
after 3 days with 5610
7 TCID50 of MVA either intravenously or
intranasally. 5 days after MVA immunization spleens were removed,
stained and analyzed by FACS. (A) Representative contour plots are
shown for CD8 T cells (CD3
+ CD8
+). Numbers show B8-specific cells as
percentage of CD8 T cells. (B) The frequencies of B8-specific CD8 T cells
are shown for each group as means 6 SD of 5 mice per group. Two
more experiments showed similar results.
doi:10.1371/journal.pone.0009659.g004
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demonstrated for LCMV [46], or the help for B cells.
The obligatory requirement of B cells and CD4 T cells for the
recovery from a lethal ECTV infection was shown by Chaudhri
et al. [13]. They used mice that completely lack B cells (B6.mMT)
f o rt h e i rs t u d i e s .H o w e v e r ,t h e s em i c eh a v em u l t i p l ed e f e c t s ,
ranging from abnormal spleen morphology to reduced numbers
of CD4 and CD8 T cells as well as dendritic cells [29,30]. Also,
the roles of B cells as professional antigen presenting cells and
antibody producing cells cannot be distinguished. Therefore, we
preferred a B cell sufficient mouse model that is unable to
produce poxvirus specific serum IgM or IgG (T11mMT)
[26–28]. In our study these mice died rapidly after 10–11 days
(Fig. 5C) and we had similar results with BCR-restricted
IghelMD4 mice [47] (data not shown). These data clearly
demonstrate that poxvirus specific antibodies are needed early to
protect mice from mousepox in a post-exposure setting. The
survival data in BCR-transgenic mice are further supported by
the IgG serum titers measured by ELISA (Table 1). Again, non-
immunized control mice and intranasally immunized mice
showed similar titers and kinetics of poxvirus specific IgG. They
had detectable IgG levels from day 9 on, which had further
increased by day 12. The only mouse that survived from these
groups was the mouse with the highest neutralizing antibody
titer (control mouse 1, Table 1). All intravenously immunized
mice had detectable IgG titers already at day 6. At every time
point the titers were higher than in the other two groups and all
mice survived.
In order to gain a more detailed insight into the functioning of
antibodies, we also performed a neutralization assay (PRNT).
PRNT titers followed the same pattern as the IgG titers measured
by ELISA. Thus, intravenously immunized mice developed high
poxvirus specific IgG titers with neutralizing capacity. Besides
neutralization, antibodies can also exert their effects via activation
of the complement cascade or ADCC. In survival experiments
using C3 deficient mice, we did not find a major role of the
complement system for the survival after post-exposure immuni-
zation (Fig. 5C). Similarly, mice lacking either the FcRc-chain or
only FccIII-receptors survived a lethal ECTV infection when
immunized three days later with MVA. This suggests that ADCC
Figure 5. Innate and adaptive immune mechanisms are required for post-exposure protection provided by intravenous MVA
immunization. Mice were infected intranasally with 3610
4 TCID50 of ECTV. (A) Wild-type C57BL/6 mice were left untreated (wt control) or
immunized (wt MVA) 3 days later with 5610
7 TCID50 of MVA intravenously. (B, C and D) All mice were immunized 3 days after ECTV infection with
5610
7 TCID50 of MVA intravenously. Survival was monitored for 32 days. The experiments were performed with the indicated number of mice, and
data show the cumulative results of 10 experiments.
doi:10.1371/journal.pone.0009659.g005
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be compensated by other immune elements when analyzed as
single missing components. NK cells are most likely required for
direct lysing of infected cells within the first few days in the
immune response.
The production of antigen specific IgG is important, but not
essential in our model since we observed a survival rate of about
50% in AID deficient mice that are unable to switch isotypes.
Surviving AID
2/2 had high poxvirus specific neutralizing IgM
titers (data not shown). It is thus possible that the lack of IgG can
be partly compensated for by the hyper production of IgM. This
also infers that the early death of MHC class II deficient mice
cannot be explained solely by the lack of help of CD4 T cells for
isotype switching in B cells. Further studies are needed to define
the exact role of CD4 T cells in this setting.
In our model intravenous application of MVA was more
potent at inducing systemic innate and adaptive immune
responses than intranasal application. This superiority was
independent of the ECTV infection as seen in vaccination
experiments with naı ¨ve C57BL/6 mice (unpublished observa-
tion). These data are in line with data from immunization
experiments done with recombinant MVA either alone or in
combination with a DNA prime [48–50]. Besides the high
immunogenicity of intravenous MVA vaccination these and our
data also demonstrate–at least in mice–the safety of this route.
The safety of intravenous MVA application was further proven in
irradiated rabbits [51]. Interestingly, a replication competent,
recombinant vaccinia virus, which is injected intravenously, is
currentlyinvestigated as an anti-cancer treatmentinclinical trials
[52]. This treatment was reported to be well tolerated, with only
mild systemic toxicity. Even thoughthese promising findings let it
seem likely that intravenous MVA immunization of humans
could be well tolerated, too, a careful investigation of possible
side effects has to be carried out.
Our results reveal the immunological mechanisms responsi-
ble for the survival of a lethal mousepox infection after
intravenous post-exposure immunization. Based on our in vivo
studies, we suggest the following model (Fig. 6): in a first line of
defence antiviral and Th1 inducing cytokines are produced that
mediate a systemic antiviral milieu and activate NK cells. NK
cells directly target and lyse ECTV infected cells and thus
bridge the time until poxvirus specific IgG is produced by B
cells. CD4 T cells are needed for B cell help but also for other
effector functions. Eventually, when ECTV is repressed by
antibodies into the cytoplasm, cytotoxic CD8 T lymphocytes
eliminate the remaining infected cells. Thus, the immune
requirements involved in post-exposure immunization clearly
differ from those involved in prophylactic vaccination, where
antibodies and B cell memory alone can provide protection to
mice against high dose ECTV challenge [19,25,37]. Of note,
there is no single parameter that can protect mice from a lethal
mousepox infection, but instead only a combination of innate
and adaptive immunity can thwart the infection. This
comprehensive activation of the entire immune system was
only achievable with an intravenous application of MVA. Thus,
it is of utmost importance to define the ideal parameters for
each vaccine in order to reveal its full potential. This becomes
especially important in cases where immediate action has to be
taken, such as bioterrorism attacks with VARV. A more
efficient induction of innate and adaptive immune responses
potentially via the application of existing vaccines via different
routes could also be beneficial in cases where standard
vaccination regimens have been unsuccessful, so far (e.g.,
cancer and HIV).
Materials and Methods
Ethics Statement
All animal experiments were approved by the government of
Upper Bavaria (Regierung von Oberbayern).
Mice
C57BL/6J mice were purchased from Harlan Winkelmann.
MHC class I deficient (B6.129-B2mtm1JaeN12) and MHC class II
deficient (B6.129-H2-Ab1tm1GruN12) mice were purchased from
Taconic Farms. IL-15Ra deficient (B6;129X1-Il15Ratm1Ama/J),
B6129SF2/J and FCcR3 deficient (B6.129P2-Fcgr3tm1Sjv/J)
mice were purchased from The Jackson Laboratory. BCR
transgenic (T11mMT), AID deficient, C3 deficient and FcRc
deficient mice were obtained from the animal facility of the
University Zurich and were on a C57BL/6 background.
Viruses
The MVA used for this study was MVA-BNH, developed by
Bavarian Nordic and deposited at European Collection of Cell
Cultures (ECACC) (V00083008). MVA was propagated and
titered on primary chicken embryo fibroblasts (CEF) that were
prepared from 11-day-old embryonated pathogen-free hen eggs
(Charles River, Massachusetts, USA) and cultured in RPMI-1640
medium supplemented with 10% FCS. ECTV strain Moscow was
obtained from the American Type Culture Collection (ATCC) as
VR-1372, and was propagated and titered on Vero C1008 cells
(ECACC 85020206). All cell lines were maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM; Invitrogen) supplemented
with 10% FCS without antibiotics. All viruses used in animal
experiments were purified twice through a sucrose cushion.
In vivo experiments
For ECTV infection mice were anaesthetized with ketamine/
xylamine and virus (3610
4 TCID50) was applied by intranasal
(i.n.) drop wise installation in a total volume of 50 ml. For i.n.
immunizations with MVA mice were anaesthetized likewise.
Intravenous (i.v.) injections were g i v e ni n t oal a t e r a lt a i lv e i nw i t h
a total volume of 200 ml. In both cases 5610
7 TCID50 of MVA
were applied. The health status of infected mice was checked
daily. For the analysis of granzyme B expression by NK and CD8
T cells mice received an injection of 250 mg brefeldin A (Sigma-
Aldrich) one day after MVA immunization. Five hours later
animals were sacrificed and spleens were immediately placed into
ice cold RPMI/5% FCS medium containing 10 mg/mL brefeldin
A. Spleen cells were further processed for flow cytometric
analyses.
Flow cytometry
Spleen lymphocytes were stained after erylysis (RBC lysing
buffer, Sigma-Aldrich) using the following monoclonal antibodies:
anti-CD3-PECy5, anti-CD3-PECy7, anti-CD4-PerCP-Cy5.5, an-
ti-CD4-APC-H7, anti-CD8-PacificBlue, anti-CD69-FITC, anti-
CD44-FITC (all BD Biosciences), anti-NK1.1-PercP-Cy5.5, anti-
CD8-Alexa700, anti-IFNc-PECy7 (all eBioscience) and anti-
Granzyme B-PE (Invitrogen). APC-conjugated MHC class I H-
2Kb dextramers loaded with B8-peptide (TSYKFESV) were used
according to the manufacturers’ instructions (Immudex). Intracel-
lular staining of granzyme B was performed after fixation/
permeabilization according to the manufacturers’ instructions (BD
Cytofix/CytopermTM, BD Biosciences). Flow cytometric analysis
was performed using a digital LSR II (BD Biosciences). Data were
analyzed with FlowJo software (Tree Star).
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Vaccinia-specific serum IgG titers were measured on days 6, 9
and 12 after ECTV infection by direct ELISA as described
previously [53]. Briefly, 96-well plates were coated overnight with
MVA antigen. Test sera were titrated in duplicate using twofold
serial dilutions starting at 1:100. As detection antibody a sheep
anti-mouse IgG-HRP (AbD Serotec) was used. The antibody titers
were calculated by linear regression and defined as the serum
dilution that resulted in an optical density of 0.30.
Plaque reduction neutralization assay (PRNT)
Vaccinia- and ECTV-specific antibodies were shown to
reciprocally neutralize infectivity [54]. In addition, cross protec-
tion experiments in mice, rabbits and chicken embryos suggest a
high cross reactivity between the two viruses [55–57]. In our
model, the antibodies are induced partly by ECTV and partly by
MVA. Therefore, we decided to use an established Vaccinia-based
PRNT assay to determine neutralizing serum antibody levels. The
PRNT assay was performed as described earlier [53]. Briefly, heat-
inactivated sera were serially diluted and incubated with vaccinia
virus Western Reserve (Advanced Biotechnologies Inc., Columbia,
MD USA). As a 100% control, virus was incubated with medium
only. After incubation the mixtures were added to pre-seeded
Vero cells and allowed to adsorb for 70 minutes. After adsorption,
pre-warmed medium was added to each well and the plate was
incubated for further 24 hours. Visualization of the plaques was
performed using a crystal violet solution (Sigma Aldrich). After
washing and drying of the plates, plaques were counted. The
neutralizing titer was determined as the serum dilution, which was
able to neutralize 50% of the mature virus, using the plaque count
in the 100% control as 100% value.
Measurement of cytokines by bead array
Serum cytokine levels six hours after immunization were
determined using mouse Th1/Th2 10plex (GM-CSF, IFNc, IL-
1a, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, TNFa) and chemokine
6plex (GM-CSF, MCP-1, MCP-3, MIP-1a, MIP-1b, Rantes)
FlowCytomix Multiplex Kits and IL-13, IL-18, IL-22 and IL-23
FlowCytomix Simplex Kits (Bender MedSystems) according to the
manufacturer’s instructions. Standard curves were generated and
samples quantified using Flow Cytomix Pro 2.2 software (Bender
MedSystems). Only MCP-1, MCP-3, Rantes, IL-6, IL-18 and
IFNc were above the level of detection.
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